295 related articles for article (PubMed ID: 36042198)
1. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
Marlin R; Desjardins D; Contreras V; Lingas G; Solas C; Roques P; Naninck T; Pascal Q; Behillil S; Maisonnasse P; Lemaitre J; Kahlaoui N; Delache B; Pizzorno A; Nougairede A; Ludot C; Terrier O; Dereuddre-Bosquet N; Relouzat F; Chapon C; Ho Tsong Fang R; van der Werf S; Rosa Calatrava M; Malvy D; de Lamballerie X; Guedj J; Le Grand R
Nat Commun; 2022 Aug; 13(1):5108. PubMed ID: 36042198
[TBL] [Abstract][Full Text] [Related]
2. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
[TBL] [Abstract][Full Text] [Related]
3. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
Guedj J; Piorkowski G; Jacquot F; Madelain V; Nguyen THT; Rodallec A; Gunther S; Carbonnelle C; Mentré F; Raoul H; de Lamballerie X
PLoS Med; 2018 Mar; 15(3):e1002535. PubMed ID: 29584730
[TBL] [Abstract][Full Text] [Related]
4. Favipiravir in SARS-CoV-2 Infection: Is it Worth it?
Batiha GE; Moubarak M; Shaheen HM; Zakariya AM; Usman IM; Rauf A; Adhikari A; Dey A; Alexiou A; Hetta HF; Al-Gareeb AI; Al-Kuraishy HM
Comb Chem High Throughput Screen; 2022; 25(14):2413-2428. PubMed ID: 35430987
[TBL] [Abstract][Full Text] [Related]
5. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.
Driouich JS; Cochin M; Lingas G; Moureau G; Touret F; Petit PR; Piorkowski G; Barthélémy K; Laprie C; Coutard B; Guedj J; de Lamballerie X; Solas C; Nougairède A
Nat Commun; 2021 Mar; 12(1):1735. PubMed ID: 33741945
[TBL] [Abstract][Full Text] [Related]
6. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
[TBL] [Abstract][Full Text] [Related]
7. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates.
Madelain V; Duthey A; Mentré F; Jacquot F; Solas C; Lacarelle B; Vallvé A; Barron S; Barrot L; Mundweiler S; Thomas D; Carbonnelle C; Raoul H; de Lamballerie X; Guedj J
Antiviral Res; 2020 May; 177():104758. PubMed ID: 32135218
[TBL] [Abstract][Full Text] [Related]
8. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.
Koshi E; Saito S; Okazaki M; Toyama Y; Ishimoto T; Kosugi T; Hiraiwa H; Jingushi N; Yamamoto T; Ozaki M; Goto Y; Numaguchi A; Miyagawa Y; Kato I; Tetsuka N; Yagi T; Maruyama S
CEN Case Rep; 2021 Feb; 10(1):126-131. PubMed ID: 32940880
[TBL] [Abstract][Full Text] [Related]
10. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models.
Kim JA; Seong RK; Kumar M; Shin OS
Viruses; 2018 Feb; 10(2):. PubMed ID: 29425176
[TBL] [Abstract][Full Text] [Related]
11. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
Luvira V; Schilling WHK; Jittamala P; Watson JA; Boyd S; Siripoon T; Ngamprasertchai T; Almeida PJ; Ekkapongpisit M; Cruz C; Callery JJ; Singh S; Tuntipaiboontana R; Kruabkontho V; Ngernseng T; Tubprasert J; Abdad MY; Keayarsa S; Madmanee W; Aguiar RS; Santos FM; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Imwong M; Taylor WRJ; Chotivanich V; Chotivanich K; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
BMC Infect Dis; 2024 Jan; 24(1):89. PubMed ID: 38225598
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA
Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821
[TBL] [Abstract][Full Text] [Related]
13. Favipiravir use for SARS CoV-2 infection.
Boretti A
Pharmacol Rep; 2020 Dec; 72(6):1542-1552. PubMed ID: 33108587
[TBL] [Abstract][Full Text] [Related]
14. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
15. Broad-Spectrum Antiviral Strategies and Nucleoside Analogues.
Geraghty RJ; Aliota MT; Bonnac LF
Viruses; 2021 Apr; 13(4):. PubMed ID: 33924302
[TBL] [Abstract][Full Text] [Related]
16. A review on favipiravir: the properties, function, and usefulness to treat COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1029-1037. PubMed ID: 33372567
[TBL] [Abstract][Full Text] [Related]
17. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
18. Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model.
Pires de Mello CP; Tao X; Kim TH; Vicchiarelli M; Bulitta JB; Kaushik A; Brown AN
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967017
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
20. Revealing the structural and molecular interaction landscape of the favipiravir-RTP and SARS-CoV-2 RdRp complex through integrative bioinformatics: Insights for developing potent drugs targeting SARS-CoV-2 and other viruses.
Chakraborty C; Bhattacharya M; Saha A; Alshammari A; Alharbi M; Saikumar G; Pal S; Dhama K; Lee SS
J Infect Public Health; 2023 Jul; 16(7):1048-1056. PubMed ID: 37196368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
